Aptevo Therapeutics Inc APVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
-
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
-
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
-
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
-
Aptevo Provides State of the Business Report and 2025 Financial Results
Trading Information
- Previous Close Price
- $4.54
- Day Range
- $4.50–4.88
- 52-Week Range
- $3.82–234.36
- Bid/Ask
- $0.00 / $0.00
- Shares Outstanding
- 1.25M
- Market Cap
- $5.98M
- Volume/Avg
- 20,969 / 38,697
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 33
Valuation
|
Metric
|
APVO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.50 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
APVO
Financial Strength
|
Metric
|
APVO
|
|---|---|
Quick Ratio | 3.05 |
Current Ratio | 3.36 |
Interest Coverage | — |
Quick Ratio
APVO
Profitability
|
Metric
|
APVO
|
|---|---|
Return on Assets (Normalized) | −134.02% |
Return on Equity (Normalized) | −255.49% |
Return on Invested Capital (Normalized) | −179.75% |
Return on Assets
APVO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Affymax Inc
AFFY
| — | Sly | — | |||
| Athersys Inc
ATHXQ
| — | Wmdys | — | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nnqcbgkyr | Zklnsy | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zjqmktqtc | Rsgsh | $64B | |||
| UCB SA
UCBJF
| — | Cplg | $61B | |||
| UCB SA ADR
UCBJY
| — | Qsc | $61B | |||
| argenx SE
ARGNF
| — | Wdnb | $56B | |||
| argenx SE ADR
ARGX
| Kwsxsyw | Nrxq | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jzkbgbktv | Ccbmpj | $38B | |||
| CSL Ltd
CMXHF
| — | Ysngzt | $36B |
United States